Release Details

CAMBRIDGE, Mass., Nov. 6, 2014 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq:IDRA), a clinical-stage biopharmaceutical company developing nucleic acid therapeutics for rare diseases, today announced the following data abstracts from its oncology programs were accepted for presentation at upcoming scientific meetings.

56^th Annual Meeting of the American Society of Hematology
December 6-9, 2014; San Francisco, Calif.

IMO-8400, an Antagonist of Toll-like Receptors 7, 8, and 9, in Development for Genetically Defined B-Cell Lymphomas: Safety and Activity in Phase 1 and Phase 2 Clinical Trials 
Session name: 624. Lymphoma: Therapy with Biologic Agents, excluding Pre-Clinical Models: Poster II 
Poster presentation time: Sunday, December 7, 2014, 6:00 - 8:00 p.m. PST 
Abstract: #3101

Novel Approach to the Potential Treatment of Patients with B-Cell Lymphomas Harboring the MYD88 L265P Mutation: Combination Treatment with TLR Antagonist and Rituximab 
Session name: 625. Lymphoma: Pre-Clinical – Chemotherapy and Biologic Agents I 
Oral presentation time: Monday, December 8, 2014, 3:30 p.m. PST 
Abstract: #508

American Association for Cancer Research Tumor Immunology and Immunotherapy Meeting 
December 1-4, 2014; Orlando, Fla.

Intratumoral Injection of IMO-2055, a Novel Toll-like Receptor 9 Agonist, with Ipilimumab Induces a Systemic Tumor-specific Immune Response 
Session name: Poster Session A 
Poster presentation time: Tuesday, December 2, 1:15 - 3:30 p.m. EST

About Idera Pharmaceuticals

Idera Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic approach for the treatment of genetically defined forms of B-cell lymphoma and rare autoimmune diseases. Idera's proprietary technology involves creating novel nucleic acid therapeutics designed to inhibit over-activation of Toll-like receptors (TLRs). In addition to its TLR programs, Idera is developing gene silencing oligonucleotides (GSOs) that it has created using its proprietary technology to inhibit the production of disease-associated proteins by targeting RNA. To learn more about Idera, visit www.iderapharma.com.

CONTACT: Investor and Media Contact

         Jim Baker
         Executive Director, Corporate Affairs
         (617) 679-5516
         jbaker@iderapharma.com